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ORIGINAL RESEARCH
Introduction: Essential tremor (ET) is the most common movement disorder in the adult
population. At present ET treatment shows limited efficacy, particularly in patients with severe
and disabling symptoms. This study evaluates the clinical efficacy of mirtazapine in an untreated
ET patient population.
Materials and methods: 30 ET patients (female/male = 19/11; average age = 71.4 ± 8.3 years)
were examined by clinical criteria, electromyographic (EMG), and apomorphine tests to study
the cortical silent period. The patients were all treated with mirtazapine 30 mg daily.
Results: Mirtazapine proved to be a good control agent for tremor symptomatology in 23/27
patients (85%) who completed 1 month of treatment, with a marked reduction of tremor; the
benefit was maintained during the 12-month follow-up. No significant variation in EMG
parameters was observed aside from two prevalent and distinct frequencies of tremors (5–
6 Hz and 7–8 Hz) and a group of selected patients whose cortical silent period (SP) was
markedly reduced. There were no clinical differences between the two subgroups. All
apomorphine-tested patients showed an SP with no significant modifications.
Conclusions: Mirtazapine proved to be an efficacious drug treatment for tremor symptoms
in patients suffering from ET. It had limited side effects and excellent overall tolerability,
could be used as daily monotherapy, and did not interfere with any of the many other
medications being taken simultaneously by the patients.
Keywords: essential tremor, postural tremor, action tremor, mirtazapine, treatment, transcranial
magnetic stimulation
Introduction
Essential tremor (ET), along with Parkinson’s disease, is a diagnosed extrapyramidal
disorder resulting in the most common movement disorders in aging adults (Brin
and Koller 1998). When it is the only neurological disorder in different members of
the same family, generally with autosomal dominant transmission, it is defined as
familiar or hereditary tremor. When diagnosed in old age it is also classified as senile
tremor. ET is characterized by a monosymptomatic postural and/or kinetic tremor
(4–8 Hz frequency) mainly related to the upper limbs symmetrically (in 10% of cases
it can appear in the dominant hand); less frequently it can also occur in other parts of
the body such as the head or it can affect the voice. The tremor is made worse by
emotions, physical exercise, and tiredness. Both males and females are equally
involved. The disease can occur even prior to the second decade of age but generally
incidence and prevalence grow with age, mainly after the age of 40 (0.4%–6.7%
prevalence in general population) reaching a specific age prevalence peak after the
age of 60 (12% of population).
Traditionally, ET has also been called “benign” while actually showing a high
degree of variability in development, ranging from the least symptomatic and
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evolutionary forms to the gradually progressive ones having
a stronger postural and mostly kinetic component which
seriously interferes with routine activities (about 10% of
cases).
Due to its relatively high frequency and appearance in
mature age, patients often reach the neurological center
believing the tremor to be an early symptom of Parkinson’s
disease. A correct diagnosis can therefore reassure most
patients on the nature and likely progression of the “tremor”
symptom.
At present ET treatment is scarcely effective, especially
for patients whose symptoms are seriously disabling. Only
two drugs have been proven equally effective in ET therapy:
propranolol (80–320 mg daily) and primidone (50–500 mg
daily) (Wasielewski et al 1998; Louis 2001). However, only
50% of treated patients report a lasting benefit, and both
drugs equally produce numerous side effects which,
especially for primidone, entails low initial dosages that
slowly and progressively increase to reach the optimal
efficacious amount to be prescribed.
A second line of therapeutic approaches has been
proposed which involves the use of clonazepam (Thompson
et al 1984), alprazolam (Huber and Paulson 1988),
gabapentin (Ondo et al 2000), methazolamide (Muenter et
al 1991), clozapine (McCarthy 1994), nimodipine (Biary
1995), and theophylline (Mally and Stone 1991). Their
effectiveness is, however, clinically insignificant and most
of all transient.
Botulinum toxin type A, which produces sustained
neuromuscular block (Jankovic et al 1996), proved
temporarily useful in reducing tremor of the hands but such
a result depends on exact choice of dosage, and number
and point of injections, so as to reduce the risk of excessive
focal muscular hyposthenia to a minimum. Finally, it should
be kept in mind that even alcohol (Koller et Biary 1984)
reduces ET. Alcohol would be difficult to propose and
manage, for it might lead to addiction or abuse, although
no increase in the rate of alcoholism has been shown in
patients suffering from ET (Koller 1983).
A number of significant clinical cases initially reported
(Pact and Giduz 1999; Gordon et al 2002) and some personal
clinical experience suggested the potential efficacy of
mirtazapine, an antidepressant that is the first in a line of
specific noradrenergic and serotoninergic antidepressants
(NaSSAs) in reducing tremor of patients suffering from
extrapyramidal diseases. Mirtazapine acts as a central
antagonist of noradrenaline α2 presynaptic receptors and
increases noradrenergic and serotoninergic transmission
while blocking the 5-HT2 and 5-HT3 receptors. A long
plasma half-life (20–40 hours), rapid achievement of steady-
state, and a high degree of tolerability, mainly for its
negligible effects on the cardiovascular system, make the
drug extremely manageable and suitable even for older
patients.
Our study aimed at evaluating the clinical efficacy of
mirtazapine in a population of patients affected by ET
presenting for the first time for observation without other
treatments for tremor.
Subjects and methods
A group of 30 patients (19 females, 11 males), aged 48–89
years (mean 71.4 ± 8.3 years) and whose clinical diagnosis
of ET was in accordance with ET principal criteria, was
included in the study. Their duration of illness was 1–40
years (mean 7.3 ± 9.4 years), and 12/30 (40%) showed a
positive family association with ET. All patients were
registered at the Neurological Operating Unit of the Busto
Arsizio District Hospital near Varese (Unità Operativa di
Neurologia dell’Ospedale di Circolo di Busto Arsizio,
Varese, Italy).
Clinical evaluation consisted of anamnestic and
neurological examination especially by observing
extrapyramidal symptoms other than tremor as well as
symptoms or signs of other “tremorgenic” neurological or
internal pathologies.
Table 1 Primary, secondary, and key criteria in ET differential
diagnosis
Primary criteria
– Bilateral action tremor of the hands and forearms (but no tremor
while at rest)
– Lack of other neurological signs, except the “gear-wheel”
phenomenon
– Isolated head tremor could be present, with no anomalous postures
or dystonies
Secondary criteria
– Long period of time (> 3 years)
– Family history
– Reduction with intake of alcoholic beverages
“To be differentiated”
– Unilateral tremor, focal tremor, tremor of the legs, walking disorder,
stiffness, bradykinesia, tremor at rest
– Sudden or rapid appearance
– Simultaneous therapy with tremor causing or tremor increasing
drugs
– Isolated head tremor with anomalous postures (bending or rotation)
Adapted from: Elble (2000).Neuropsychiatric Disease and Treatment 2006:2(1) 97
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The ET diagnosis formulated was in accordance with
the guidelines established by the Tremor Investigation Group
and by the Consensus Statement of the Movement Disorder
Society (Deuschl et al 1998; Elble 2000) which point out
“primary” essential criteria and “secondary” supporting
criteria (Table 1)
All patients also underwent a biohumoral screening that
included thyroid functioning as well as tremor “grading”
carried out according to a 5-point rating scale (0–4)
(Table 2). All evaluations were carried out by an examiner
who was “blind” to the pharmacological treatment received
by the patients. The scale used enabled study of the
frequency, as well as the amplitude and the interference with
activities, of the different kinds of tremor being examined.
Resting tremor was rated as the patient sat comfortably on
a chair with relaxed limbs. Postural tremor was rated with
Table 2 Tremor rating scale
0 1234
Adapted from Deuschl (1987).
A – Resting tremor absent slight,
intermittent,
small amplitude,
hardly disturbing,
controlled by will
moderate,
constant,
amplitude is variable but
less than 50 mm,
disturbing to the subject,
can be controlled by
will
serious,
constant,
amplitude ranging from
50 to 100 mm,
very disturbing for the
subject, 
only temporarily
suppressed by will
very serious,
constant,
over 100 mm amplitude,
disabling,
hardly controlled by will
B – Postural tremor
(Rated with glass full to the
brim)
absent slight,
intermittent,
small amplitude,
hardly disturbing,
no spilling from glass
moderate,
constant,
variable amplitude but
still slight,
not very disturbing for
the subject,
intermittent and slight
dripping from glass
serious,
constant,
average amplitude
interferes with many
activities,
constant dripping from
glass
very serious,
constant,
considerable amplitude,
hindering activities,
marked dripping from
glass
C – Action tremor
C1: in alternating
flexion/extension
arm movements
C2: in reaching a target
(index-nose test)
absent slight,
intermittent,
small amplitude,
hardly disturbing,
controlled by will
moderate,
constant,
amplitude is variable but
less than 50 mm,
disturbing to the subject
serious,
constant,
amplitude ranging from
50 to 100 mm,
interferes with many
activities
very serious,
constant,
over 100 mm amplitude,
hindering activities
D – Orthostatic tremor absent slight,
intermittent,
small amplitude
slight,
constant,
with variable oscillations
moderate,
constant,
average amplitude,
can interfere with
balance
serious,
constant,
with broad oscillations,
can be disabling
E – Tremor of the head absent slight and intermittent slight but constant,
not disturbing
moderate,
constant,
interferes with some
activities
serious,
constant,
interferes with most
activities
F – Speech normal slight tremor of the
voice,
not steady,
no difficulty in making
oneself understood
slight tremor of the
voice,
constant,
occasional difficulties in
making oneself
understood (rarely needs
to repeat sentences)
moderate tremor of the
voice,
pronouncing words
distinctly now and then,
constant,
a few incomprehensible
sentences need to be
repeated
serious tremor of the
voice,
articulating words and not
very understandable
G – Writing normal slightly impaired, but
legible
moderately impaired, but
every word is legible
seriously impaired,
a few words illegible
illegible
H – Overall subjective
disability
absent slight, variable slight, constant moderate seriousNeuropsychiatric Disease and Treatment 2006:2(1) 98
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stretched arms. Action tremor was studied while the patient
performed an alternating flexion–extension movement of
the arm and hand (simple action tremor) and differentiating
it from tremor that might occur during the “index-nose”
test performance (specific action tremor). Lastly, the patient
was asked to evaluate subjectively the overall tremor-caused
disability on the quality of his/her own life.
On completing the clinical study the patients were
morphologically examined (computerized tomography or
magnetic resonance) in order to exclude any significant
alteration of the brain, and they also underwent electro-
myographic (EMG) tremor evaluation with surface
electrodes of antagonist muscles (finger common flexor and
finger common extensor, short abducent of the thumb and
first dorsal interosseous) while at rest and when maintaining
posture.
When examining patients whose sole extrapyramidal
disorder is tremor, many studies have demonstrated that
modifications occur both in the characteristics of the evoked
potential motion (EPM) of the cortex and in the inhibiting
phenomenon defined as the cortical silent period (SP) typical
of the most important extrapyramidal syndromes. Such
stimulating and inhibiting phenomena were thus evaluated
and compared with the standard data we had acquired. The
patients were therefore studied for their EPM and SP as
well as the EMG tremor plot throughout the test, including
evaluation of SP modification by the apomorphine test.
To carry out the EMG test a MAGSTIM model 200
magnetic stimulator (Magstim Company Ltd, Whitland,
Wales, UK) was employed which had a “high power”
14-mm diameter coil located on the vertex with a counter-
clockwise flux current. EMG activity was recorded on the
subject while comfortably sitting, hands supine, tracing via
Ag–AgCL surface electrodes from the short adductor of the
thumb (SAT) and first dorsal interosseous, or from two
antagonist muscles of the forearm (finger common flexor
and finger common extensor) by means of a NICOLET
VIKING 2 testing unit (Nicolet Biomedical Inc, Madison,
WI, USA), processing the signal through a band passing
filter between 20 and 2 Hz.
For the EPM tests, the optimal position on the scalp for
stimulation was found by establishing the EPM having the
greatest amplitude and highest stimulus output (80%–100%
1.5 Tesla). Subsequently, the stimulus was reduced to detect
the threshold of EPM (the minimum stimulus intensity able
to elicit an EPM of around 50–100 µV in about 50% of 10
consecutive responses, as suggested by Cantello et al (1991).
The optimal position was usually situated 10–20 mm in front
of and 50–60 mm on the side of the vertex while the coil
was kept tangential to the scalp with an angle about 45°
from the median line.
The measurement of the length of central, post-EPM SP
was obtained by averaging 4–6 stimulations during a
continuous tonic contraction corresponding to about 50%
of the maximum strength of the target muscle (usually SAT)
with the super maximal stimulus intensity (80%–100 %).
Each stimulation was repeated alternately on both sides of
the scalp shunting from counterlateral target muscles.
Domperidone (a specific peripheral antagonist of
dopaminergic receptors unable to cross the hemato-
encephalic barrier) was given by mouth in a dose of 20 mg
thrice daily 3 days before going through the test, to prevent
any possible side effect (nausea and vomiting) induced by
apomorphine. The patient’s clinical examination was carried
out before and about 15, 20, and 30 minutes after the
subcutaneous injection of 2 mg of apomorphine chlorhydrate
(10 mg/mL), immediately following the recording of the SP.
After completing the diagnostic examination procedure,
all patients were treated with mirtazapine 30 mg daily once
in the evening, and they went through clinical re-
examination and EMG check-ups 30 days after initiating
the treatment. Those patients who responded to the treatment
were re-examined again clinically 3 months later, and
subsequently on a 3-monthly basis.
Statistical analysis of the non-parametric variables was
performed by means of Wilcoxon’s rank test. Parametric
variables were compared by ANOVA. Statistical significance
level was set at p < 0.01.
Results
The SP of the population generally appeared to fall within
standard limits or was markedly reduced, reappearing in
relation to tremor frequency and the resetting phenomenon
due to cortical stimulus. The frequency pattern fell mainly
between 5 and 6 Hz, although a small group of 6 patients
(20%) showed a 7–8 Hz frequency. The EMG study almost
solely pointed to a tremor synchronism between agonist and
antagonist muscles. All the data further confirmed that the
EMG characteristics of all patients were in accordance with
the ET diagnosis.
Throughout the study, treatment with mirtazapine
showed a tolerability profile that seemed favourable in most
cases, only 3 patients had to stop taking the treatment
because of undesirable circumstances (undue drowsiness
in 2 cases and excitement in 1 case).Neuropsychiatric Disease and Treatment 2006:2(1) 99
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Effectiveness of the treatment was analyzed by observing
27 patients who had completed the first month of treatment.
Mirtazapine assured good control of tremor symptoms in
23/27 patients (85%). A statistically significant difference
was found for these patients when comparing basal and post-
treatment evaluations dealing with postural tremor, action
tremor, tremor of the head, and for speech and writing
(Table 3). Furthermore, overall subjective disability
improved significantly for those patients with a great
variation between basal and post-treatment assessments
(2.17 ± 0.53 vs 1.13 ± 0.73, p < 0.001).
The subgroups consisting of those patients who did or
did not show a family history for tremor were then compared,
but no statistically significant differences were found. A
differential analysis was also carried out on subgroups with
different tremor frequencies (< 7 Hz and ≥ 7 Hz), but again
no differences of statistical relevance were found for
treatment efficacy.
Finally, none of the apomorphine-tested patients showed
important modifications in their SP, and the pharmaco-
logical treatment with mirtazapine did not bring about
any substantial variation in their electrophysiological
parameters.
Discussion
Our study, an open-label design but with a “blind” observer,
suggests that mirtazapine is a valuable drug in assuring
effective control of tremor symptoms. Of 27 patients
suffering from ET who received at least 1 month of
treatment, 85% gained substantial benefit, and the benefit
persisted essentially unchanged for 6 months in 75% of the
cases and for up to 1 year after starting the treatment in
55% of the cases (15 patients have in fact already completed
their first year of treatment).
The patients included in the study had EMG
characteristics that were in accordance with the ET diagnosis
(Deuschl et al 1987), and the apomorphine test did not
determine any remarkable change in their SP compared with
what can commonly be observed in patients suffering from
the tremor-causing syndrome of Parkinson’s disease
(Manfredi et al 1998).
During the EMG examination two distinct main tremor
frequencies were also detected (5–6 Hz and 7–8 Hz) and a
group of patients whose SP was considerably reduced was
also identified. These characteristics were not, however,
associated with any element that could clinically differentiate
the two subgroups and did not seem to be connected to
treatment response; mirtazapine was found to be equally
effective in both subgroups of selected patients. Similarly,
the clinical efficacy of mirtazapine did not appear to be
linked to a family history for tremor symptoms.
Our data, therefore, seem to agree with the preliminary
observations reported (Pact and Giduz 1999; Gordon et al
2002), which pointed out the clinical efficacy of mirtazapine
in those pathological states characterized by tremor, both
of the Parkinson’s and the essential type, suggesting a
specific action of the drug on that symptom.
Tolerability also proved to be good, with a reduced rate
of drop-outs. Only 3 out of the 27 patients who completed
the trial felt a small sedation/drowsiness during daytime,
most noticeable during the first weeks of treatment, but these
patients continued the treatment nonetheless. Three patients
complained about a slight gain in weight (about 2–3 kg).
Only one patient wished to stop taking mirtazapine,
notwithstanding the excellent control over tremor, because
of a considerable gain in weight. No anomalies were detected
either in the hematological or in other biohumoral indexes
during the observation phase. Finally, mirtazapine did not
alter the electrophysiological parameters throughout the
treatment.
For those patients who stopped taking the drug or did
not respond to the treatment it must be noted that they were
older with more complicated case histories, and sometimes
they had received previous treatment (beta-blockers,
benzodiazepines, anticholinergics, primidone) that had not
given the desired results or had been only partially effective.
The very many co-morbidities (high blood pressure in
40%, dysthymia/anxiety in 26.6%, diabetes in 13.3%),
together with the relevant therapies to be undertaken, did
Table 3 Clinical evaluation of essential tremor (ET) before and
after 1 month of treatment with mirtazapine (30 mg/daily)
(number of patients = 27)
Before After
treatment treatment p
Resting tremor – – –
Postural tremor 2.11 ± 0.42a 1.19 ± 0.56 < 0.01
Action tremor
C1: in alternating
flexion/extension arm
movements 1.41 ± 0.64 0.74 ± 0.71 < 0.01
C2: in reaching a
target (index/nose test) 1.56 ± 0.75 0.89 ± 0.58 < 0.01
Orthostatic tremor – – –
Tremor of the head 0.96 ± 1.01 0.48 ± 0.70 < 0.01
Speech 1.07 ± 0.96 0.59 ± 0.69 < 0.01
Writing 1.67 ± 0.68 0.89 ± 0.70 < 0.01
Overall subjective disability 2.15 ± 0.53 1.04 ± 0.65 < 0.01
a Values are means ± standard deviation of mean.Neuropsychiatric Disease and Treatment 2006:2(1) 100
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not show interference problems in association with a
combined intake of mirtazapine. Depression symptoms of
patients suffering from mood disorders also generally
improved. Although a quarter of patients were affected by
dysthymia/anxiety, they did not show different responses
compared with the remaining patients.
Mirtazapine is an antidepressant with noradrenergic and
serotoninergic actions; some of the clinical efficacy of the
drug may be related to its sedative or anxiolytic effects
(especially on the psychogenic component of postural and
action tremors), but our impression is that mirtazapine
performs its action independently.
In summary, mirtazapine proved to be extremely
valuable for treating tremor in patients suffering from ET,
with rare side-effects, because of its mono administration,
tolerability, and non-interference with any concomitant
therapy. The subjective benefit was most evident and lasting
for all patients who responded to the treatment (over 80%)
and who then wished to continue. Lastly, mirtazapine was
effective in all patients afflicted with ET, irrespective of their
electrophysiological and/or hereditary characteristics, with
unchanged efficacy and of long duration.
New studies, preferably double-blind and placebo-
controlled, should be performed on the role of mirtazapine
in the treatment of different types of tremor in order to
confirm the promising results of our study and of other
preliminary studies.
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